In our previous studies, we demonstrated that the introduction of phytonutrients including lipoic, caffeic, and ferulic acids into the chemical scaffold of acetylcholinesterase inhibitors such as rivastigmine [32] and tacrine [33,34,35] leads to new molecules, which retain the cholinesterase inhibitory activity and show antioxidant and chelating properties, thus proving to be valuable disease-modifying candidates to treat AD. The gene discussed is BCHE; the disease is Alzheimer disease.